Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Lund, Sweden, October 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from ...
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Lund, Sweden, October 22, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the t ...
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Lund, Sweden, September 9, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months del ...
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study
Lund, Sweden, August 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today interim safety data from its ongoing clinical ...
Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020
Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical d ...
Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology
Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced ...
Alligator Bioscience’s collaboration with Biotheus Inc. proceeds and second payment is received
Lund, Sweden, June 1, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 ...
Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015
Lund, Sweden, May 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data ...